Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

Overview of attention for article published in Frontiers in oncology, August 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

So far, Altmetric has seen 1 X post from an account with 6,541 followers.

New Research: Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option https://t.co/JBrdffaRbY #FrontiersIn #Oncology

14 Aug 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.